SAN FRANCISCO, May 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical
company, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018, after market close,
and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT).
Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website,
www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the
start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the
call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and
use passcode 46778299#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 46778299#
About FibroGen
FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of
China, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class
therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth
factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and
cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase
activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), except in China,
where a New Drug Application is currently under review by the China Food and Drug Administration (recently reformed as the State
Drug Administration, or SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe, and expected to shortly enter
Phase 2/3 development in China, for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF
monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and
pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a
biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact
FibroGen, Inc.
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications
1 (415) 978-1433
kbergman@fibrogen.com